Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNM-Au8 for Visual Pathway Deficits in MS
NCT03536559Phase 2Terminated
- Sponsor
- Clene Inc.
- Start
- Nov 2018
- Primary completion
- Apr 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of CNM-Au8 in relapsing-remitting multiple sclerosis (RRMS), sponsored by Clene Inc.. Started Nov 2018; status: terminated.
02
Drugs
CNM-Au8
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT03536559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03536559.